Source Link
Excerpt:
The Senate on Thursday confirmed anti-aging research investor Jim O’Neill for the second-highest position at the Department of Health and Human Services, a step toward an era of deregulation in biomedical research from the highest levels of the department.
O’Neill, President Donald Trump’s nominee to serve one step below HHS Secretary Robert F. Kennedy Jr. as deputy secretary, was confirmed on partisan lines in a vote of 52 to 43.
O’Neill’s long record of funding anti-aging research and advocacy for deregulation in bringing new health innovations to market could become a new pillar of the Make America Healthy Again agenda, reshaping federal public health programs.
During the first Trump administration, O’Neill was floated as a nominee to lead the Food and Drug Administration because of his work on FDA reform during his six-year tenure in the George W. Bush HHS. He was ultimately passed over for the role in favor of Dr. Scott Gottlieb.
.jpg%2F500px-Donald_Trump_(53953173435).jpg&f=1&nofb=1&ipt=1eb09485c9f1cd57919082677e15526c735bd86eb8152493e737ff4709ce030d)
